Alzheimer’s disease has beaten back another effort to tame it.

Biogen (BIIB) and its Japanese pharma partner Eisai said Thursday that they were halting two Phase 3 clinical trials of aducanumab, a drug that was designed to slow the worsening of Alzheimer’s by targeting brain-destroying protein fragments known as beta-amyloid.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • wow all the eggs in one basket just brilliant, lost 16 BILLION dollars…yet I’ll bet the CEO makes millions in bonuses and if made to leave which they should be, will get a golden parachute worth MILLIONS for nearly destroying or who knows maybe actually destroying a company

  • No doubt AA removing the plaques should work to improve the outcome of the disease but the wholes remain and the disease would progress

  • Trying to stop Alzheimer’s once it is going, is a hopeless proposition unless somebody can show that neural cells can regenerate. A situation that we now is unreal. Removing plaque can create more problems, plaque immobilizes toxic amyloid-beta oligomers, hence removing plaque increases the concentration of free toxic components. While aducanumab may have protective effects, there are myriad amyloid beta oligomers, which means you would need an array of antibodies to block the different flavors of toxic amyloid. Perhaps a mixture of different antibodies would be more effective. Once amyloid oligomers are formed, they promote tau phosphorylation that amplifies damage; thus, an after the facts blocking of amyloid oligomers is too late too little. Finally, immune prevention is a more realistic goal than try to cure what apparently is incurable

    • I wonder if anyone tried going other way. Pushing oligomerization toward plaques – to prevent toxicity of oligomers. As far as I understand plaque amounts in brain do not correlate to AD symptoms (i.e healthy individuals might have more plaques than AD patients). It is very disappointing and very sad for families with AD patients. 🙁

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy